New drug hope for kids with rare Muscle-Weakening disease
NCT ID NCT06149559
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and researchers monitor side effects and changes in antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mg0006 20081
Taipei, Taiwan
-
Mg0006 20095
Taipei, Taiwan
-
Mg0006 20339
Ōbu, Japan
-
Mg0006 20340
Fuchu-shi, Japan
-
Mg0006 20343
Sagamihara, Japan
-
Mg0006 40144
Milan, Italy
-
Mg0006 40155
Warsaw, Poland
-
Mg0006 40290
Bologna, Italy
-
Mg0006 40733
Naples, Italy
-
Mg0006 40734
Warsaw, Poland
-
Mg0006 40836
Kocaeli, Turkey (Türkiye)
-
Mg0006 40841
Altindağ/ankara, Turkey (Türkiye)
-
Mg0006 40843
Ankara, Turkey (Türkiye)
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rozanolixizumab
What this could lead to
If it works, this could provide a new treatment option for children with generalized myasthenia gravis, helping control muscle weakness and improve daily life.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply to all children. The drug may cause serious side effects like infections or headaches.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.